A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Who Have Received Two or Three Prior Systemic Chemotherapy Regimens

CTX-009 simultaneously targets, binds to and blocks DLL4 and VEGF-A. This prevents the activation of DLL4/Notch- and VEGF-A/VEGF receptor (VEGFR)-mediated signaling pathways, which play key roles in angiogenesis and tumor vascularization. This prevents angiogenesis and may halt tumor cell prolifration.

In this study, the sponsor and investigators want to learn:

• The effects of the study drug (good and bad)
• How the study drug is acting on your body
• How much of the study drug is absorbed into the blood and how fast it is removed

The study regimen will be given in cycles.  Each cycle is 28 days.  You will receive the study drug every 14 days, on day 1 and day 15 of every cycle. The study drug will be given as an IV infusion into a vein over 1 hour.